WTO Dispute Resolution and the Preservation of the Public Domain of Science Under International Law (with R. Dreyfuss)

Graeme B. Dinwoodie, Chicago-Kent College of Law

Available at: https://works.bepress.com/graeme_dinwoodie/30/
WTO dispute resolution and the preservation of the public domain of science under international law

GRAEME B. DINWOODIE
ROCHELLE COOPER DREYFUSS*

Abstract

I. Introduction

II. Upstream patenting and its relationship to technological progress

III. Hypothetical solutions and their international implications

A. Subject matter exclusions
B. Exemptions

1. Article 30’s “three-part test”
   (a) Scope of Uses: “Limited” Exceptions
   (b) Economic Impact: Conflict with Normal Exploitation
       (i) National Practices
       (ii) Typical Means of Exploiting the Patent
       (iii) Source of Commercial Capacity
   (c) Types of Uses: Unreasonable Prejudice to Legitimate Interests

2. Article 27’s technological neutrality

C. Remedies

IV. Concluding observations

ABSTRACT

The TRIPS Agreement can be read to reflect a static view of the structure of intellectual property law. In this paper, we address whether – and how – the TRIPS Agreement can be interpreted to give it more fluidity, and thus to allow adjustments in national intellectual property regimes designed to reflect the dynamic nature of information production. To focus that inquiry, we concentrate on efforts to ensure a broader public domain for “upstream” inventions by modifying various elements of US patent law. The paper considers three stylized examples and asks whether each approach could be adopted by the United States without falling afoul of the TRIPS Agreement, as it is currently understood. Our purpose is to identify interpretive approaches that allow member states to keep their laws attuned to the developments and needs of science. In so doing, we also raise broader questions regarding the level of formalism generated by the WTO dispute settlement system, and the extent to which the TRIPS Agreement

* Graeme Dinwoodie is Professor of Law and Norman & Edna Freehling Scholar, Director, Program in Intellectual Property Law, Chicago-Kent College of Law; Rochelle Cooper Dreyfuss is Pauline Newman Professor of Law, New York University School of Law. The authors wish to thank Brian Havel, Tim Holbrook, and Carlos Correa for comments on an earlier draft of this paper. Thanks also to participants in Rebecca Eisenberg and Molly Van Houweling’s patent law workshop at the University of Michigan, and to the Filomen D’Agostino and Max E. Greenberg Research Fund at NYU for financial support. Copyright 2004, Graeme B. Dinwoodie and Rochelle Cooper Dreyfuss.
allocates power between supranational and national institutions, and between international and national laws.

I. Introduction

The size and content of a rich public domain are affected by a constellation of national intellectual property rules: provisions that define protectable subject matter, establish threshold requirements for protection, delineate the scope of the rights awarded, create defenses and exemptions from liability, and set remedies for infringement. Since 1995, the Agreement on Trade-Related Aspects of Intellectual Property (the TRIPS Agreement) has imposed specific limitations on the contours of these rules, and it thus serves to regulate on an international level the ways in which members of the WTO can shape the contents of the private and public domains.

At the time the TRIPS Agreement was negotiated, the main focus of attention was on codifying then agreed-upon norms of protection. As a result, the Agreement can be read to reflect a static view of the structure of intellectual property law. Information production is, however, a dynamic enterprise. Additions to the domain of knowledge can change the intellectual landscape and thereby alter the creative opportunities—and challenges—facing artists and inventors. New industries emerge, others mature; nations have traditionally administered, interpreted, and modified their rules to achieve the balance between public and private rights that is appropriate, at any given time, for each field. The question we address in this article is whether—and how—the TRIPS Agreement can be read with equivalent fluidity, in order to allow adjustments in national regimes that reflect the dynamic nature of information production. In a sense, this problem is not new, as many of the WTO nations have operated under the constraints of international obligations for over a century. Nonetheless, the TRIPS Agreement raises unique concerns because it addresses a broader range of issues than prior instruments and, as the first global intellectual property agreement to include a compliance mechanism, it has unprecedented bite.

To focus the inquiry, we concentrate on efforts in United States patent law to ensure a broader public domain for “upstream” inventions, that is, for discoveries so directly related to fundamental principles that they dominate broad swaths of inventive opportunities. The expansion of

---

1 Public access to intellectual products can also turn on who owns the rights and how the owner exploits the work. See, e.g., Arti K. Rai & Rebecca S. Eisenberg, Bayh-Dole Reform and the Progress of Biomedicine, 66 LAW & CONTEMP. PROBS. 289 (2003) (arguing that funding agencies should have greater authority to demand patent rights in fundamental research results produced by universities in government-funded projects).


3 We concentrate on patent law rather than on other intellectual property regimes because it confers a greater level of exclusivity and is concerned with cutting-edge developments that are most likely to undermine core assumptions of intellectual property
patentable subject matter to include upstream inventions has led concerned observers to suggest that other elements of patent law must also be modified in order to re-create public-domain space in which work can be undertaken in accordance with traditional scientific norms. To be sure, expanding the categories or the scope of protectable subject matter in domestic law comports with a basic premise of the TRIPS Agreement, which leaves considerable discretion to WTO members to provide protection in excess of mandated minimum levels. But these proposed modifications, by contracting protection, would arguably raise TRIPS-compliance concerns and thus bring into question the resilience of the Agreement.

The public domain could be reconstituted in a variety of ways: by modifying the definition of statutory subject matter, elevating the threshold for protection, adjusting the scope of rights, creating new exemptions, or imposing new types of relief. Its contours could also be changed by revising non-intellectual property regimes (including administrative and procedural law) and by altering the mechanisms and institutions that facilitate private ordering. Evaluating a broad range of approaches would allow us to fully probe the provisions of the TRIPS Agreement to see which are most hospitable to protecting the public domain of science. At this point, however, we look at only three stylized examples. These are: (1) excluding certain discoveries from the subject matter of eligible patent protection; (2) creating a statutory exemption that gives courts discretion to permit unauthorized uses of sufficient social significance; and (3) varying the right to relief. This article asks whether each approach could be adopted by the United States without falling afoul of the TRIPS Agreement as it is currently construed.

Our purpose is not to predict the outcome of future disputes—there are far too few WTO precedents for that. Rather, our goal is to identify interpretive approaches that allow members to keep their laws attuned to the developments and needs of science. We also raise broader questions regarding the level of formalism generated by the WTO dispute settlement system, and the extent to which the TRIPS Agreement allocates power between supranational and national institutions, between international and national laws.

II. Upstream Patenting and its Relationship to Technological Progress

As suggested earlier, there is growing concern that prospects for innovation are jeopardized by trends in U.S. patent law that increasingly recognize private claims to core principles of knowledge, of special significance to

---

4 See below text accompanying nn. 6-11.
basic research. At one time, science was considered distinct from technology, and intellectual property law was predicated on the existence of an analogous doctrinal boundary between basic and applied research. Increasingly, however, United States patent law recognizes private claims that cross the border between fundamental knowledge and commercial application. This development may reflect the science-intensive nature of modern technology, which makes recent advances inherently dual in character; it may also be caused by changes in the organization of science, including the reliance of small, highly networked knowledge-intensive firms on patents to signal technical and business competence, or by the emergence of research organizations (such as universities) that look to patent rights to support fundamental research. Whatever the cause, patent protection has moved upstream.

The net result is troublesome. Patents may now confer power not only in product markets, but also in innovation markets. As such, these patents can have broad significance. Because second comers can often invent around end-use inventions, patents rarely monopolized product markets. In contrast, a patent on, say, the structural information of a protein, or on a metabolic pathway, or a computer operating system, could give the patentee control over all work involving that protein or pathway, or all opportunities to create application programs for that system. As a result, there is growing evidence suggesting that—at least in the United States—patent rights over research opportunities have begun to hinder progress by chilling innovation and impeding the production of new knowledge.

---

6 See, e.g., Brenner v. Manson, 383 U.S. 519 (1966) (defining the utility required for patent protection as end-use rather than research-use utility). See also Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 131 (1948) (holding that packets containing mixtures of bacteria were "no more than the discovery of some of the handiwork of nature" and hence unpatentable); O'Reilly v. Morse, 56 U.S. (15 How.) 62 (1853) (holding that abstract principles are not statutory subject matter).

7 See, e.g., Diamond v. Chakrabarty, 447 U.S. 303 (1980); State St. Bank & Trust Co. v. Signature Fin. Group, Inc., 149 F.3d 1368 (Fed. Cir. 1998), cert. denied, 119 S. Ct. 851 (1999). See also Francis Narin & Dominic Olivastro, Status Report: Linkage Between Technology and Science, 21 RES. POL’Y 237 (1992) (using citation measures to demonstrate that the tie between science and technology is becoming closer over time and is more pronounced in drugs, medicine, chemistry, and computing than in fields such as machinery and transportation).


10 In this context, product market means the market for products, processes, and the products of processes.

11 See, e.g., Rebecca S. Eisenberg, Bargaining Over the Transfer of Proprietary Research Tools: Is This Market Failing or Emerging?, in EXPANDING THE BOUNDARIES, above n. 8. See generally, NATIONAL RESEARCH COUNCIL, A PATENT SYSTEM FOR THE 21ST CENTURY 59-64 (Stephen A. Merrill et al. eds., 2004).
III. Hypothetical Solutions and Their International Implications

There is considerable debate among policymakers on such matters as whether the benefits of these developments outweigh their costs and whether private parties will find their own ways to contract around potential bottlenecks. In this article, however, we ask a different question: what can national legislators who perceive a problem do to fix it, consistent with their countries’ international obligations under the TRIPS Agreement?

A. Subject matter exclusions

The most direct way to deal with the problem of upstream patenting might be to define patentable subject matter in a way that excludes inventions with significant upstream applications from eligibility for protection. This approach could be implemented across the board, or limited to areas where evidence suggests that the chill to research is potentially great. Although drawing such lines would be difficult, advocates of this approach claim it is superior to alternative means of protecting the public domain because it creates bright-line rules on which investors can rely.

For example, Richard Epstein has suggested that the “use value” of patents—their value in product markets—should be compared to their “blocking” value—their upstream significance in innovation markets. When the blocking value exceeds the use value in a particular field, inventions within that field should not be considered patentable. He gives the example of expressed sequence tags (ESTs), short sequences of coding DNA, noting that while the useful applications of ESTs barely meet the utility standard of current patent law, “[e]ach EST is a gateway to some gene on which useful work could be done.” Since the primary use of a patent on an EST would thus be to block others from entering that gateway, Epstein argues that such patents should not issue.

John Barton takes a different approach. He would exclude specific subject areas whenever the blockage problem becomes acute. He gives as an example, proteomics—information about the shape of the body’s protein molecules that is crucial to understanding and predicting how the body will respond to pharmaceutical interventions.

Would such carve-outs meet the requirements of article 27.1 of the TRIPS Agreement, which provides that, subject to defined exceptions, “patents shall be available and patent rights enjoyable without discrimination as to the . . . field of technology”? To analyze that question, one can usefully distinguish between de iure and de facto forms of discrimination. In the former situation, specific fields of technology are

14 TRIPS Agreement, above n. 2, art. 27.1.
carved out for special treatment; in the latter, rules that are facially neutral have disparate effects on particular subject areas.

The language of article 27 is clearly aimed at prohibiting de iure discrimination with respect to the availability and enjoyment of patent rights. The legislative history of the Agreement is replete with indications that a primary concern of the negotiators was to eliminate blanket exclusions of certain types of patentable subject matter (most notably drugs, agrochemicals, and foodstuffs). Thus, a subject matter exclusion directed at biotechnology generally, or at specific areas within biotechnology, such as proteomics, would almost certainly run afoul of the Agreement.

An approach that comes conceptually closer to Richard Epstein’s suggestion is, however, more difficult to analyze. Facialy, the approach is neutral—it would bar patents on discoveries of predominantly upstream significance in every field of technology. Nonetheless, it would more profoundly affect fields that are science-intensive and fields where the targets of protection have high informational content. For example, it would have greater impact on biotechnology and computer science than on chemistry or mechanical engineering. Thus, while the proposal would not directly implicate the motivating rationale for article 27.1, its potentially disparate effect on different fields could conceivably fall afoul of the literal text of article 27.

Thus far, there have been no decisions directly addressing subject matter exclusions under article 27, but we inform our analysis with the observation that WTO panels tend to hew closely to text when resolving disputes. For example, the panel in Canada-Pharmaceutical Products considered article 27 in the course of reviewing the TRIPS consistency of two exemptions that Canada had enacted in its patent law. One of these, the so-called regulatory review exemption, permitted use or manufacture of a patented invention solely for purposes of obtaining regulatory approval. The intent was apparently aimed at promoting competition between generic and proprietary pharmaceutical companies by facilitating market entry by generics at the moment of patent expiration. While the exemption was expressed in technologically neutral language, the European Union argued that its impact on the pharmaceutical industry violated article 27.1 under, essentially, a disparate impact theory.

The WTO panel rejected the EU’s specific contention, but only after Canada assured it that the exemption was indeed neutral in the sense that it was legally available to every product subject to marketing approval requirements. In fact, the panel agreed with the EU’s larger point, that the

---


Agreement barred both *de iure* and *de facto* discrimination. In other words, it appears that under this decision, the mere lack of a textual limitation to particular fields will not immunize a provision from challenge.

Still, it may be possible to salvage Epstein’s approach. Patent laws tend to apply differently across industrial sectors, depending on such factors as the level of skill in particular fields. It is difficult to believe that members of the WTO would have so readily committed themselves to altering this approach to their domestic lawmaking. Indeed, the panel acknowledged as much, stating, “article 27 does not prohibit bona fide exemptions to deal with problems that may exist only in certain product areas.”

In fact, the panel’s report can be read as prohibiting *de facto* discrimination only when the claim includes some additional element, such as an allegation of an intent to discriminate. Thus, the panel stated, “it was not proved . . . that the objective indications of purpose demonstrated a *purpose to impose disadvantages* on pharmaceutical patents in particular, as is often required to raise a claim of *de facto* discrimination.” While panels, both in the TRIPS and broader WTO contexts, have acknowledged the difficulty of identifying (and scrutinizing) the purposes behind particular national laws, we find it entirely appropriate that those claiming *de facto* discrimination should be required to demonstrate some element—such as intent—over and above those required to establish *de iure* cases of discrimination. At the very least, those defending an exclusion should be permitted to rebut a showing of disparate treatment by demonstrating a legitimate purpose. What these demonstrations might entail we leave to another day, but they might be satisfied by, for example, demonstrating a close linkage between the exclusion and the particular organizational or institutional structure (such as a bifurcated generic and proprietary drug industry—or a decision to rely on patents to selectively support fundamental research) in the country in question.

The foregoing suggests that variations in result must be evaluated carefully when determining whether national law violates the technological-neutrality principle. Discrimination is not the same as differential treatment. This is not to foreclose the possibility that a claim for *de facto* discrimination under article 27.1 could succeed; but this reading does suggest that nations retain power to modify their notions of statutory subject matter along the lines of the Epstein proposal in order to deal with changes in the relationship between basic science and end-use technologies.

---


18 See Canada-Pharmaceutical Products, above n. 15, ¶ 7.92.

19 *Id.*, at ¶ 7.105 (emphasis added).

20 See United States–Section 110(5) of the US Copyright Act, WTR/DS/160/R (WTO Dispute Settlement Panel 2000) [hereinafter United States–Section 110(5)].

In fact, even more targeted carve-outs of the sort proposed by Barton may be permissible. Although we recognize that such a conclusion runs headlong into the literalism that panels have exhibited in interpreting TRIPS, if a legitimate policy objective can be effectuated by a narrow, technology-specific exclusion, we fail to see why article 27.1’s commitment to formal neutrality should force WTO members to adopt exclusions that are broader than necessary. Such an approach would appear to run counter to the underlying thrust of the TRIPS Agreement toward enhanced protection. We address this paradox below in connection with our discussion of article 30.22

B. Exemptions

To the extent that the problem with upstream patents is their capacity to block pure research, another solution would be to permit certain activities to be undertaken without a patentee’s authorization, in return for payment of a nonmarket-based rent (or for free). For example, Maureen O’Rourke proposed a patent law exception, analogous to the fair use defense of copyright law, tailored to the unique concerns of the patent industries. Her analysis would consider (i) the nature of the advance represented by the infringing work; (ii) the purpose of the infringing use; (iii) the nature and strength of the market failure that prevents a license from being concluded; (iv) the impact of the use on the patentee’s incentives and overall social welfare; and (v) the nature of the patented invention.23 A court would use these factors to determine whether a patented invention could be used without authorization, and also to assess royalties.

Professor O’Rourke’s proposal, if enacted into domestic law, could indeed solve the upstream patent problem by freeing patented inventions for use in fundamental research. However, articles 27 and 30 of the TRIPS Agreement each present problems for this approach.

1. Article 30’s “three-part test”

Article 30 provides that exceptions from liability for patent infringement are permissible if they (a) are limited, (b) do not unreasonably conflict with a normal exploitation of a patent, and (c) do not unreasonably prejudice the legitimate interests of the patent owner, taking account of the legitimate interests of third parties. O’Rourke’s proposal appears to accommodate these criteria by requiring courts to consider similar parameters. This conclusion, however, is not without doubt because there is a question whether WTO adjudicators will tolerate the amount of discretion that this approach gives to domestic courts. Certainly, the factors that courts consider when exercising that discretion would become critical to a finding of TRIPS-compatibility.

22 See text below at n. 54.

Our analysis of the relevant issues is informed by two panel reports, *Canada–Pharmaceutical Products* discussed above, and *United States–Section 110(5).* In the former, two exemptions were challenged: the regulatory review exemption described earlier, and a stockpiling exemption that enabled the generic industry to manufacture patented products within the last six months of a patent term (for sale upon expiry of the term). Two exemptions were also at issue in the *Section 110(5)* case, both of which permitted the playing of recorded copyrighted music in commercial establishments. In each case, it was claimed that the exemptions at issue satisfied each of the cumulative three steps of the applicable test for permissible exceptions (article 30 for patents, article 13 for copyright).

(a) Scope of Uses: “Limited” Exceptions. The *Canada-Pharmaceutical Products* panel stated that the term “limited,” which is found only in article 30, required that the exemption be a narrow one, which the panel measured by reference to the extent to which the rights of the patentee were curtailed. The stockpiling exemption was found not to be “limited” because, during the last six months of the statutory term, it negated all protection under three of the patentee’s five guaranteed rights (make, use, or sell) with no limitations on the quantities produced or the market destination of the products. In contrast, the regulatory review exemption was considered “limited” because it narrowly curtailed the patentee’s exclusive rights. The extent of the acts permitted (i.e., those that were necessary to comply with the regulatory approval process) was small and narrowly bounded.

On its face, O’Rourke’s proposed exemption resembles the invalid stockpiling exemption in that it would appear to curtail potentially all of a patentee’s exclusive rights. One could certainly argue that if a provision was facially unlimited, then it should be doomed. However, the Appellate Body has cautioned that panels should not assume that a member would act inconsistently with its international obligations. If, in fact, courts develop

---

24 See *Canada-Pharmaceutical Products*, above n. 15; United States – *Section 110(5)*, above n. 20.

25 See *TRIPS Agreement*, above n. 2, arts. 13, 30.

26 The first step of the copyright test confines copyright exceptions to “certain special cases,” which requires, among other things, that the exception be clearly defined. United States–*Section 110(5)*, above n. 20, ¶¶ 6.107-6.110.

27 The panel concluded that the first step in the three-step test does not require consideration of the economic impact of the exemption because that concern was taken up by the second and third steps of the test. See *Canada-Pharmaceutical Products*, above n. 15, ¶ 7.49. Thus, even if the adoption of the proposed fair use or experimental use exemption did give rise to substantial economic impact (because, for example, protecting research opportunities represents a large part of the patentee’s return at present), that would not of itself prevent the exemption from being regarded as limited.

28 In certain respects, the panel appeared to be incorporating some of the considerations relevant to analysis under article 31, which governs the grant of compulsory licenses, into the article 30 analysis.

29 *Canada-Pharmaceutical Products*, above n. 15, at ¶ 7.45.

principles that limit the broad language of O’Rourke’s proposal to bring it closer to the approved regulatory review exception, then it should satisfy the first step of the three-step test in article 30.

(b) Economic Impact: Conflict with Normal Exploitation. The Canada-Pharmaceutical Products panel concluded that the normal practice of exploitation was “to exclude all forms of competition that could detract significantly from the economic returns anticipated from a patent’s grant of market exclusivity.”31 Courts could ensure compliance with this standard most directly by considering whether a challenged domestic provision compromised significant economic opportunities.32 Yet, the defense might survive challenge even if it were to render non-infringing certain uses or acts for which patentees currently extracted payment. The notion of normalcy should not be static but should evolve through successive interpretations of article 30 by panels, the Appellate Body, the TRIPS Council, and future ministerial negotiations.33 As the two panels acknowledged, while this understanding should take account of national practices, especially with regard to typical means of exploiting the patent and the source of that commercial capacity, normalcy is ultimately a normative question—it depends on a vision of the just balance between proprietary rights and public access interests, and not purely on past practices. We suggest that the factors mentioned by the panels and the Appellate Body should be considered, but that the normative question should permeate the entire analysis.34

(i) National Practices. In part, the Canada-Pharmaceutical Products panel treated the ability to exploit the invention exclusively even after patent expiration as normal because it was typical. Here the panel may have meant that several WTO members had established premarket clearance procedures that effectively prolonged the period of exclusivity beyond the time of patent expiration.35

31 Canada–Pharmaceutical Products, above n. 15, ¶ 7.55.
32 Such an approach might appear unduly internationalist in the current political climate. Thus, we would rest on the canon of statutory construction that instructs judges to interpret domestic law, where possible, in accordance with international obligations.
33 Cf., Declaration on the TRIPS Agreement and Public Health, WT/MIN(01)/DEC/2, ¶ 5 (WTO Ministerial Conference, 14 Nov. 2001) (“while maintaining our commitments in the TRIPS Agreement, we recognize . . . flexibilities”). The traditional sources of customary international law (including member state institutions) might also supply meaning to the concept.
34 These factors are not meant to be exclusive; in other cases, additional considerations may be relevant.
35 Canada-Pharmaceutical Products, above n. 15, at ¶ 7.56. It is possible that the panel was referring to the fact that some post-exploitation was typical of patents generally or that it was employed by “most patent owners.” Thus, in rejecting Canada’s categorical assertion that post-expiration market exclusivity could not be normal, the panel obliquely referred to the fact that “some of the basic rights granted to all patent owners, and routinely exercised by all patent owners, will typically produce” such exclusivity. Id. at ¶ 7.56 (emphasis added). Likewise, the panel rejected the EU’s argument that patent expiration should be irrelevant to normalcy because it did not address itself to the panel’s view of normal, namely, it did not offer a “demonstration that most patent owners extract the value of their patents in the manner barred by the [challenged exemption].” Id. at ¶ 7.58 (emphasis supplied). Thus, although the panel sought to examine what was “common
In one sense, O’Rourke’s proposal does well under this subtest. Exemptions to support research are, in fact, typical of member states’ intellectual property laws. For example, the United States has long had an experimental use defense for work that is solely for the “purpose of gratifying a philosophical taste.”36 So, too, do other industrial nations, such as Japan and Germany.37 Moreover, the EU is currently proposing exemptions for “acts done privately for non-commercial purposes,” and for “acts done for experimental purposes relating to the subject-matter of the patented invention.”38 In another sense, however, O’Rourke’s proposed approach could be in trouble. The “typical” defense is extremely narrow;39 because O’Rourke’s proposal is multi-factored and heavily based on judicial discretion, it will be difficult to predict its applicability to any given situation. The resulting uncertainty could act as a drag on patent value.

Nonetheless, we think the proposal can be salvaged. Although state practice is clearly relevant to the creation of customary international law, existing national laws should not of themselves be permitted to entrench an international norm. Such an approach exalts national laws inappropriately. The norms of international law are cautiously and appropriately driven by concerns of consensus and permitting variations in national laws. National laws represent a more ambitious attempt to articulate an ideal norm suited to a more focused and homogenous context.

Furthermore, because states are generally free to exceed internationally mandated minima, there is a baseline issue: a denial of exclusivity may be from a level of protection that exceeds the internationally mandated standard. Privileging a particular national standard would, in fact, be somewhat perverse. States would have a hard

within a relevant community,” Canada-Pharmaceutical Products, above n. 15, at ¶ 7.54, it did not carefully define the “relevant community.” Moreover, in United States-Section 110(5), the panel declined to address the EU’s contention that “comparative references to other countries with a similar level of socio-economic development could be relevant to corroborate or contradict data from the country primarily concerned.” See United States – Section 110(5), above n. 20, ¶ 6.189.


time experimenting with higher levels of protection if international intellectual property law prevented them from later re-assessing and restoring the level of protection to one that hews closer to the minimum standard.

Moreover, barring reforms of this type would prevent WTO members from adjusting their national laws to accommodate changing economic and social circumstances. It would thus validate the refrain of many critics of recent international intellectual property developments that the system operates as a one-way ratchet. Indeed, the Canada-Pharmaceutical Products panel suggested as much, noting that “the specific forms of patent exploitation are not static . . . for to be effective exploitation must adapt to changing forms of competition due to technological development and the evolution of marketing practices.”

Because it is the complexity of modern technology that gives rise to the complications in O’Rourke’s proposal, an argument could be made that the proposal would be consistent with typical national practice.

(ii) Typical Means of Exploiting the Patent. In determining normalcy for purposes of article 30, the Canada-Pharmaceutical Products panel may alternatively have been considering what right holders regard as typical exploitation practices. However, it was clearly unwilling to rely on that ground alone. Likewise, the United States–Section 110(5) panel held that the extent to which rights holders actually exercised their rights could not be “fully indicative of normal exploitation.” Indeed, both panels offered a definition of “normal” that explicitly encompassed a normative assessment as well as an empirical analysis of what was “regular, usual, typical or ordinary.”

The application of this subpart to O’Rourke’s approach is difficult to reckon. In part, there is another baseline issue. As noted earlier, it was not typical for rights holders to assert control over innovation markets in the past; now it has become more common. Neither panel provided a time frame in which typical exploitation should be judged, yet it is difficult to see how practices in 2004 have any greater claim to determine normalcy than practices in 1994. Thus, restoring the level of protection to that which

---

40 Canada-Pharmaceutical Products, above n. 15, ¶ 7.55. Admittedly, this language appears largely directed at efforts to expand forms of exploitation, but the general proposition holds true.

41 United States–Section 110(5), above n. 20, ¶ 6.196. The patent standard in article 30 (but not the copyright equivalent in art. 13) allows such conflicts provided they are reasonable. It would thus appear to afford member states greater latitude on the second leg of the patent exceptions test. But in both provisions, the permissible conflict is measured against the same norm, that is, “normal exploitation.”

42 See id. ¶ 6.166 (“dynamic…approach, i.e., conforming to a type or standard”); Canada-Pharmaceutical Products, above n. 15, ¶ 7.54 (“The term ‘normal’ can be understood to refer to an empirical conclusion about what is common within a relevant community, or to a normative standard of entitlement.” The panel concluded that the word ‘normal’ was being used in article 30 in a sense that combined the two meanings.).
existed before the line between basic and applied research was blurred could pass muster.\textsuperscript{43}

We are especially concerned that despite the panels’ language, neither set of adjudicators took the normative dimension seriously; neither went so far as to articulate a normative vision of exploitation. Instead, as Jane Ginsburg has commented, the analysis in the \textit{Section 110(5)} case sought only to “anticipate what the empirical situation [would] be, [rather] than [provide] an explanation of what the right holder’s markets should cover.”\textsuperscript{44} The literature includes a rich body of intellectual property theory, and the opening for normative assessment provides a vehicle for panels to use this scholarship to develop international law. Of course, a commitment to a broader approach would inevitably draw panels into more intrusive assessments of national legislative values. But, as the Appellate Body recognized in its first TRIPS report,\textsuperscript{45} and as the \textit{United States–Section 110(5)} panel hints in its discussion of “normal,” it is the responsibility of panels to make critical assessments of national law.\textsuperscript{46} Presumably, a WTO member defending an exemption of this type could aid the adjudicators by elaborating on the normative underpinnings of its approach (as O’Rourke did in her article).\textsuperscript{47}

\textbf{(iii) Source of Commercial Capacity.} The \textit{Canada-Pharmaceutical Products} panel declined to treat as normal the “additional period of de facto market exclusivity created by using patent rights to preclude submissions for regulatory authorization” because it was “not a natural or normal consequence of enforcing patent rights.”\textsuperscript{48} Instead, it was the product of a combination of patent laws and the regulatory approval scheme—a commercial rather than a legal effect.

Clearly, a rigorous inquiry into the nature and source of control should inform the analysis. Enhanced commercial exploitation may arise from the availability of technological protection measures that reinforce statutory rights; from contracts that parties enter on account of industry

\textsuperscript{43}See above text accompanying n. 7.
\textsuperscript{45}India-Patent Protection for Pharmaceutical and Agricultural Chemical Products, WT/D550/AB/R (WTO Appellate Body 1997).
\textsuperscript{46}Determining the contexts in which international norms should trump national determinations will obviously depend on both the substantive intellectual property values and systemic values underlying the international system. The Appellate Body seems to have left room for deference to national welfare considerations if not in direct conflict with the literal text. See TRIPS Agreement, above n. 2, Preamble; J.H. Reichman, \textit{Securing Compliance with the TRIPS Agreement After U.S. v. India}, 1 J. INT’L ECON. L. 585, 597 (1998).
\textsuperscript{47}Indeed, an interpretative approach that encourages articulation of the rationales behind national legislation may greatly enhance the transparency of national law, to the benefit of intellectual property lawmakers. See Graeme B. Dinwoodie & Rochelle C. Dreyfuss, \textit{TRIPS and the Dynamics of Intellectual Property Lawmaking}, 36 Case West Res. J. INT’L L. 95 (2004).
\textsuperscript{48}Canada-Pharmaceutical Products, above n. 15, ¶ 7.57.
structure or because the costs of challenging an exclusive right outweighs the benefits of cooperation; or more darkly, from market power and undue commercial leverage. Absent such inquiry, invalid assertions of rights and the flexing of market muscle may be elevated to international law.

This analysis is not, however, helpful to O’Rourke’s proposal, which is clearly aimed at curbing a control created by force of law. Nevertheless, it is important to remember that the conclusion on normalcy depends on an interaction of relevant factors, not a cumulative satisfaction of each. The entire analysis must also be infused with normative content. To the extent that O’Rourke is preserving a competitive research (as opposed to end-use) market, her proposal furthers the goals of intellectual property law.

c. Types of uses: Unreasonable Prejudice to Legitimate Interests. As the Canada-Pharmaceutical Products panel acknowledged, the third step of article 30 clearly involves a normative assessment. Thus, much of what we said above is relevant here. However, because upstream patenting is new, there is no international norm that deals with its impact on the research environment.

When the Canada-Pharmaceutical Products panel found that there was no controlling international norm in that case, it suggested deference to local autonomy, and that approach may well support the O’Rourke proposal, were it adopted by the United States. As noted earlier, the traditional market for patented inventions is a product market; the right to control research is, in most fields, slim. Hence, removing rights over innovation markets in sectors where they are suddenly available should not be regarded as prejudicing a legitimate interest (especially if all of the other forms of exploitation continue to be recognized). Members of the WTO should be free to realign the components in their constellation of patent law rules and to restore the stable universe that once existed.

The validity of the exemption is bolstered by the last clause of the third step in article 30, which (unlike its copyright counterpart in article 13) explicitly calls for a panel to “take account of the legitimate interests of third parties.” The panel hinted that considerations such as society’s interest in promoting progress, and scientists’ interest in free inquiry, might be considered “legitimate” within the meaning of article 30. Further, although the panel cautioned that articles 7 and 8, which speak of promoting technological innovation to the mutual advantage of producers and users, and of protecting public health and promoting the public interest, cannot be used to reargue the balance struck in article 30 of the TRIPS

49 Id. at ¶ 7.73.
50 Id., at ¶ 7.82. Cf. India—Patent Protection for Pharmaceuticals, above n. 45, ¶¶ 46, 59. This approach illustrates that pro-public goods arguments might flow either from substantive intellectual property preferences embedded in the TRIPS Agreement, or from neo-federalist principles found in the international intellectual property system.
51 See above text accompanying nn. 42-43.
52 Canada-Pharmaceutical Products, above n. 15, ¶ 7.69.
Agreement, they can shed light on the meaning of “legitimate interests.”53 Thus, if the availability of the exemption depends, as O’Rourke contemplates, on market failures that preclude contracts that would advance overall social welfare, a panel might accept the argument that the exemption was TRIPS-consistent.

2. Article 27’s technological neutrality

Another possible challenge to O’Rourke’s approach is rooted in the technological neutrality principle of article 27, which the Canada-Pharmaceutical Products panel read as imposing an additional hurdle for WTO members seeking to invoke article 30 to justify domestic exemptions to the exclusive rights required by international patent law. The panel appeared to regard article 27.1 as a structural provision, part of the fabric of the Agreement as a whole, which can be transposed to the analysis of other provisions.

If article 27 does apply to exemptions within article 30, the O’Rourke proposal appears vulnerable to challenge. Although this “fair use” exemption would not be aimed at specific subject matters of invention, it is likely that it would play out differently in different fields. Indeed, the fifth factor in the O’Rourke analysis—the nature of the patented invention—makes this possibility explicit.

We believe, however, that the O’Rourke approach is appropriate because the policy concerns that underlie her analysis are more acute in some fields than in others. To put this another way, we think the panel was wrong in applying article 27.1 to exemptions. As noted earlier, there are good reasons why different technologies or different uses may require different judicial or legislative treatment. It seems counterproductive to require socially desirable exemptive solutions to extend to all technologies when technology-specific problems require technology-specific solutions.54

Indeed, requiring exemptions to be technologically neutral appears particularly anomalous in that it tends to make a broader than necessary exemption more sustainable under international law than a narrow exemption. This outcome conflicts with the norm contained in article 30 that expressly requires the availability of exemptions to be evaluated in terms of whether any given exemption is “limited.” A targeted exemption that differentiated between different types of invention would limit a patentee’s rights only in areas where there was a perceived imbalance between public and private interests. Regardless of whether a panel might be more sympathetic to an exemption that is cast in general terms, the policies underlying the TRIPS Agreement favor exemptions that are either targeted or, though framed broadly, evolve to permit particular limited

53 Id. ¶ 7.26.
54 If the approach of the Canada-Pharmaceutical Products panel prevails, we could present this argument under the rubric that, as explained above, a mere difference in treatment of different technologies might not amount to discrimination in violation of art. 27. See above text accompanying nn. 14-21.
uses. A formalist commitment to technology neutrality is inconsistent with a purposive reading of the TRIPS Agreement.

To sum up, an analysis of O’Rourke’s proposal produces a mixed picture. On the one hand, strong arguments could be made that the scope of the exempted uses should be regarded as limited; as having an acceptable economic impact; and as not interfering with legitimate interests. But these arguments will be accepted only if panels assess article 30 issues through a normative filter. A panel would also have to agree with us that the structural use of article 27 is a mistake. If a more literalist view is taken, the proposal may not be regarded as acceptable. It requires faith in the discretion of domestic courts, it produces uncertainty and therefore potentially reduces patent value. Moreover, it permits unprecedented intrusions into important innovation markets that are protected by the force of patent law, and it is specifically crafted to have a differential impact on upstream technologies.

C. Remedies

A third way to protect the public domain of science is to vary the terms of relief so as to immunize upstream researchers from liability for patent infringement. One idea, proposed by one of us and modified by Richard Nelson, would benefit non-commercial research organizations, especially universities and their employees, if 1) the patented materials they wished to utilize were not made available on reasonable terms; 2) the investigators agreed to publish their research results; and 3) the investigators agreed either to refrain from patenting the research results or to patent and then license the result on a nonexclusive basis and on reasonable terms.55

The compatibility of this solution with TRIPS obligations is difficult to gauge in light of the disputes resolved so far because none of them has involved remedial issues.56 Immunizing certain users from liability could be categorized as an exemption to the right conferred and analyzed under article 30.57 If so, then the argument would be similar to the one set out above, with the added observations that this approach curbs the judicial discretion that engendered some ambivalence in our analysis of the open-ended exemption. It also seems unlikely to intrude seriously on


56 United States—Section 211, above n. 30, discusses remedies, but not in ways that would substantially influence our analysis here.

57 Cf. Mossinghoff, above n. 55, at 796 (examining the surgical immunity provision under art. 30).
the patentee’s own interests. While it could reduce markets for research tools, only those markets that the patentee refused to supply would be affected. Some opportunities may also be lost in the innovation market, but because these opportunities would likely be non-commercial fundamental research opportunities, they are likely to be rather low on a profit-minded patentee’s own priority list.

We are not, however, convinced that article 30, standing alone, should provide the appropriate framework of analysis. While article 30 imposes well-established strictures of international law on what WTO members can do, the TRIPS Agreement as a whole appears to envision far more latitude at the remedial phase. The flexibility that the TRIPS Agreement preserves is most evident in article 41, which sets out WTO members’ enforcement obligations. Subsection 5 explicitly provides that members are not required to enforce intellectual property law in a manner different from how they enforce their laws in general. This deference makes considerable sense. Members need discretion to choose the means by which they satisfy effective enforcement obligations because enforcement implicates questions of resources and institutional priorities that go to the heart of national political ordering in ways that far transcend intellectual property law.

Other more specific remedies provisions also create substantial flexibility. Article 45 requires WTO members to give judicial authorities power “to order the infringer to pay the right holder damages adequate to compensate.” However, when a court exercises that authority, adequacy is measured entirely by local conditions. In markets where demand for the product—or ability to pay—is low and in markets that have price controls in place, the compensatory award will be low. The award will, in other words, reflect local conditions, desires, and needs. This is as it should be: a patent is a right to exclude, not a right to exploit.

Even the provisions that protect the right to exclude can be read as creating substantial space for sovereign interests. Although article 44.1 requires member states to give judicial authorities power to order injunctive relief, nothing in the provision expressly requires courts to enter such orders. United States law reads the same way in that it is interpreted to give courts considerable discretion to tailor injunctions to specific (local) conditions.

Given this degree of flexibility, an approach based on remedial immunity should be considered consistent with the TRIPS Agreement.

58 TRIPS Agreement, above n. 2, art. 41.
59 Id. art. 45.
60 TRIPS does not apparently proscribe price controls, although some effort to do so has reportedly been made in bilateral negotiations.
Monetary rewards could be reduced to zero for the same reasons that monetary relief is traditionally low in some situations: the relevant user groups—in this case, non-commercial research institutions—lack resources to pay for the inputs they need. Moreover, the economic value of the use—in this case, basic research—is highly speculative, and courts do not generally award speculative damages.62

Injunctive relief is also denied for familiar reasons, sounding in the need to deal with important social problems. In this case, that might include an organizational structure for science in which fundamental and applied scientific research are conducted in different institutions or in networked environments. It could also be considered an effort to deal with cultural aversions to entering into binding transactions with strangers in the face of scientific and business uncertainty.

Admittedly, relief under this proposal is withheld across the board, rather than on the typical case-by-case basis. Yet, efficiency or other values often require the articulation of a rule that constrains equitable discretion and reduces reliance on case-by-case analysis.63 An approach to the enforcement provisions of TRIPS that prevented a WTO member from choosing between a case—by—case or a rule-based approach might be thought to impose on such a member the obligation to enforce intellectual property law in a manner different from the enforcement of laws generally. Indeed, where TRIPS negotiators thought that members had to be constrained in permitting a broad rule-based approach to adjudication, they included a provision to that effect.64 Finally, the requirement of “effective remedies” in article 41.1 is preserved in that the patent remains valuable for many purposes. For example, it can be used to extract remuneration in other markets, and it retains its value as a signal to potential collaborators and investors.

As a matter of policy, it makes sense that the net result should be that member states retain authority to control the terms on which basic research is conducted. Given that members appear free to hold down the profits that innovators can earn by such actions as permitting parallel imports, or imposing compulsory licenses or price controls,65 it is important that they remain equally free to control the costs that innovators face. Otherwise, price could, in theory, fall to the worldwide demand price (or to the price set by the government with the most stringent price controls),

62 In United States contract law, speculative damages are not available. See, e.g., ReSTATEMENT (SECOND) OF CONTRACTS § 352 (1981) (“damages are not recoverable for loss beyond the amount that the evidence permits to be established with reasonable certainty.”).
63 For example, in intellectual property cases it is presumed that irreparable harm will ensue if the plaintiff with a likelihood of success on the merits could not obtain preliminary injunctive relief.
64 See TRIPS Agreement, above n. 2, art. 31(a); see also DANIEL GERVAIS, THE TRIPS AGREEMENT: DRAFTING HISTORY AND ANALYSIS 165 (Sweet & Maxwell 1998).
65 TRIPS Agreement, above n. 2, arts. 6, 31.
while the costs of research and development would be entrenched by the Agreement.66

IV. Concluding Observations

Our case studies demonstrate that a country that perceives a problem with the patenting of upstream research has a variety of ameliorative approaches at its disposal, each with different pay-offs as a matter of domestic policy. Subject matter carve-outs are easy to administer, but hard to legislate; exemptions may be easier to legislate, but difficult to administer; and changing remedies has limited application. These approaches are also likely to provoke different responses at the international level. Unless article 27 of the TRIPS Agreement is read narrowly, subject matter exclusions may be impermissible; while an open-ended exemption could be heavily dependent upon a domestic interpretation that tracks international standards. Although the immunity approach may have the best chance of being approved by the WTO, it may be thought to violate remedies obligations, especially for patented technologies that are principally utilized in basic research.

Should the TRIPS Agreement be read to constrain national choices in this formalistic way? Consider, for example, the provision of current United States law on which the immunity defense outlined above was based. It immunizes a “medical practitioner’s performance of a medical activity” that would otherwise constitute infringement. If the analyses of articles 30 and 44 that we put forward are rejected, then this provision could also be found to violate the TRIPS Agreement. Yet, a subject matter approach to surgical method patents would clearly be upheld under article 27.3(a), which permits members to exclude surgical methods from patentability.67 It is difficult to see why WTO panels should adhere strictly to this formalistic approach, which requires these choices to be analyzed separately.

Of course, formalism may have a role to play. Our analysis also raises the question whether any provisions of the TRIPS Agreement are what we have called structural or horizontal in nature, part of the fabric of the Agreement as a whole, which should be transposed to the analysis of other provisions. The Canada-Pharmaceutical Products panel appeared to regard article 27.1 as one such provision and superimposed its technological neutrality principle on article 30. Although the Agreement no doubt contains some provisions (such as national treatment) that possess this structural character, panels should be cautious before elevating any particular provisions to this status, especially when these are ostensibly

66 Arguably, the immunity approach could be viewed as a government subsidy that violates other provisions of the General Agreement on Tariffs and Trade. However, subsidization of basic (as opposed to applied) work has long been regarded as permissible. See, e.g., Mary Lowe Good, Technology and Trade, 27 Law & Pol'y INT’L BUS. 853, 857-58 (1996).

67 See TRIPS Agreement, above n. 2, art. 27.3(a).
directed at specific issues rather than delineated in that part of the Agreement that addresses General Provisions and Basic Principles.68

In its latest TRIPS report, United States–Section 211, the Appellate Body attached great weight to the characterization of the law being challenged.69 Such formalism may be necessary in the early stages of a lawmaking enterprise. However, characterization must be performed with attention to substantive goals. In multistate private litigation where choice of law is an issue, courts have long used a similar process. In those cases, the forum does not regard itself as bound by the characterization of the state that enacted the rule, but instead it makes its own assessment based on the state interests that underlie the law.70 In our present context, WTO panels should do likewise, especially in the early years when they are considering state laws that were not formulated with TRIPS categories in mind. The appearance of arbitrariness will best be avoided by a process of characterization that is alert to the substantive purposes of intellectual property law.

It is also important for panels to keep what might be called the “neo-federalist” underpinnings of the TRIPS Agreement in mind. The Agreement, as an instrument of intellectual property law, must strike a balance between sufficient levels of protection to stimulate the desired social and commercial activity undertaken by first-comers, and sufficient limits on those rights to ensure the maximum socially useful exploitation of that activity. It partly achieves this balance substantively by allocating rights as between private and public interests, that is, between producers and users of intellectual property. But the Agreement does not articulate an international code authoritatively fixing that balance. It could not because the precise balance is still heavily contested within individual countries. Furthermore, where a particular country has settled on a specific balance, there is no guarantee that that balance would optimize the supply of innovation in a country of different competitive structure or economic status.

TRIPS, like any international agreement, must also deal with issues such as sovereignty, diversity, and legitimacy that pervade international relations. It must accordingly allocate power between supranational and national institutions, between national and international laws. Even when prescriptive power resides at the international level, that power is typically the authority to set boundaries within which a WTO member can act rather than to impose a specific rule of law. But when power remains vested in the members, their governments have substantial legislative discretion, subject only to structural principles of the international intellectual property
and trade regimes. In the TRIPS context, these allocations have the additional effect of giving WTO members an important role in striking the producer/user balance of intellectual property law.\(^71\)

In the discussion above, much of our argument rested on recognizing the importance of this neo-federalist structure. Thus, a decision to allow WTO members to create a larger public domain by one method or another may be a product not of an intellectual property balance that the TRIPS Agreement mandated, but rather a consequence of the conferral of autonomy on national governments. For our case study, it seems to follow that the United States can enact a particular regime not because it embodies a balance between public and private interests that was struck in the TRIPS Agreement, but rather because that Agreement allows its members to make a range of determinations, of which the one adopted by the United States is a permissible option.

To put it another way, because the TRIPS Agreement was negotiated with the goal of promoting international trade, the goals of substantive balance common to domestic intellectual property systems are barely discernable in its provisions. Nevertheless, panels must take seriously the autonomy interests implicit in the structure of the international intellectual property system, and they must allow sovereigns to respond to changes in science, to the structure of their patent industries, or to other social needs. Otherwise, a series of worldwide disutilities will result. These include costs stemming from the imposition of a uniform balance of producer and user interests which is in fact suitable for only one or a few countries, and inefficiencies caused by the long-term entrenchment of a balance appropriate for one point in time.\(^72\) The goals of intellectual property law will thus be subverted, not furthered, by the international regime. The costs of disregard for autonomy interest of states will also be borne by the international intellectual property system, whose long-term legitimacy and credibility rests in part upon participating states being best able to achieve the international welfare goals that purport to be at the root of the system.

In passing, we have suggested various systemic values that are crucial to this approach to analyzing TRIPS obligations: the incentives likely to optimize social utility may vary widely from country to country. Permitting some diversity of approach allows nation states to act as laboratories in the development of international rules; affording space for the self-determination of sovereign states encourages voluntary and ultimately more effective compliance with international norms. Besides, universality may have costs, whether measured in economic or non-economic terms. We plan to develop these systemic values at greater

---

\(^71\) Characterization will also be a tool for implementing the principles of neo-federalism that we discuss above. Cf. Dicey & Morris, above n. 70, at 2-039 (noting that in private multinational litigation, characterization by a forum is simply the refinement or redefinition of the forum’s conflicts rule).

length in another article. Fully articulating the latitude afforded WTO members under international intellectual property law will provide scholars and national policymakers with a sense of the boundaries within which these domestic debates can then occur.